Aberrant neurofilament protein and synaptophysin expression in malignant melanoma of the nasal cavity

Antonella Coli(Università Cattolica del Sacro Cuore), Guido Massi(Università Cattolica del Sacro Cuore), Marco Alessandrini(Università Cattolica del Sacro Cuore), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Giulio Bigotti(Università Cattolica del Sacro Cuore), Pier Giorgio Giacomini(Università Cattolica del Sacro Cuore), Silvia Ferraro(Università Cattolica del Sacro Cuore)
Histopathology
February 1, 2004
10.1111/j.1365-2559.2004.01784.x
Cited by 21

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2020|530
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2017|501